Doravirine/lamivudine/tenofovir disoproxil fumarate

Phase 2Small molecule

Doravirine/lamivudine/tenofovir disoproxil fumarate is one of 44 small molecule programs targeting Immunodeficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Repatha

Amgen

Phase 3

1 3

Emtriva

Gilead

Phase 3

1 4

Edurant Ped

WWim Janssens

Phase 3

8 5

Vemlidy

Gilead

Phase 3

—6

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Livalo

MMedicure

Phase 3

1 8

Immunoglobulin

Sanofi

Phase 3

2 9

Atripla

Gilead

Phase 3

3 10

PPSV23

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency2 trials

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02629822·10 enrolled

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03272347·123 enrolled

First-line1 trial

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

Completed·PProfessor Francois Venter·Phase 3·NCT04433780·133 enrolled

HIV1 trial

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

Recruiting·UUniversity Hospital, Caen·Phase 2·NCT06034938·32 enrolled

Tenofovir Disoproxil Fumarate1 trial

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03332095·55 enrolled

Tenofovir1 trial

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

Unknown status·TThomas Benfield·Phase 4·NCT04903847·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Doravirine/lamivudine/tenofovir disoproxil fumarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doravirine/lamivudine/tenofovir disoproxil fumarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doravirine/lamivudine/tenofovir disoproxil fumarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Doravirine/lamivudine/tenofovir disoproxil fumarate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency2 trials

First-line1 trial

HIV1 trial

Tenofovir Disoproxil Fumarate1 trial

Tenofovir1 trial

References

Drug Info

Quick Facts

Related News